PHARMACOKINETICS AND SAFETY OF VIR-2218 MONOTHERAPY IN ADULT CIRRHOTIC PARTICIPANTS WITH MODERATE HEPATIC IMPAIRMENT

被引：0
|
作者：
Wang, Li [1 ]
Chattergoon, Michael A. [1 ]
Elie, Sophia [1 ]
Wu, Pan [1 ]
Hristopoulos, George [1 ]
Gupta, Sneha [1 ]
Reyes, Maribel [1 ]
机构：
[1] Vir Biotechnol Inc, San Francisco, CA USA
来源：
HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1480C
引用
下载
收藏
页码：S581 / S582
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics of VIR-2218, an RNAi therapeutic for the treatment of HBV infection, in healthy volunteers
    Gupta, Sneha V.
    Fanget, Marie C.
    Bakardjiev, Anna
    Robbie, Gabriel I.
    Goel, Varun
    Mogalian, Erik
    JOURNAL OF HEPATOLOGY, 2020, 73 : S885 - S885
  • [2] Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection
    Sneha V. Gupta
    Marie C. Fanget
    Christopher MacLauchlin
    Valerie A. Clausen
    Jing Li
    Daniel Cloutier
    Ling Shen
    Gabriel J. Robbie
    Erik Mogalian
    Drugs in R&D, 2021, 21 : 455 - 465
  • [3] Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection
    Gupta, Sneha, V
    Fanget, Marie C.
    MacLauchlin, Christopher
    Clausen, Valerie A.
    Li, Jing
    Cloutier, Daniel
    Shen, Ling
    Robbie, Gabriel J.
    Mogalian, Erik
    DRUGS IN R&D, 2021, 21 (04) : 455 - 465
  • [4] PRELIMINARY 48-WEEK SAFETY AND EFFICACY DATA OF VIR-2218 ALONE AND IN COMBINATION WITH PEGYLATED INTERFERON ALFA IN PARTICIPANTS WITH CHRONIC HBV INFECTION
    Yuen, Man-Fung
    Lim, Young-Suk
    Cloutier, Daniel
    Thanawala, Vaidehi
    Shen, Ling
    Elie, Sophia E.
    Arizpe, Andre
    Cathcart, Andrea L.
    Lau, Audrey H.
    Hwang, Carey
    Gane, Edward
    HEPATOLOGY, 2022, 76 : S19 - S20
  • [5] An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib
    Magee, Mindy He
    Shearn, Shawn
    Shaddinger, Bonnie
    Fang, Zixing
    Glaser, Ruchira
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (05) : 1014 - 1021
  • [6] Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
    Akce, Mehmet
    El-Khoueiry, Anthony
    Piha-Paul, Sarina A.
    Bacque, Emeline
    Pan, Peng
    Zhang, Zhi-Yi
    Ewesuedo, Reginald
    Gupta, Divya
    Tang, Yongqiang
    Milton, Ashley
    Zajic, Stefan
    Judson, Patricia L.
    O'Bryant, Cindy L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (05) : 825 - 836
  • [7] Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
    Mehmet Akce
    Anthony El-Khoueiry
    Sarina A. Piha-Paul
    Emeline Bacque
    Peng Pan
    Zhi-Yi Zhang
    Reginald Ewesuedo
    Divya Gupta
    Yongqiang Tang
    Ashley Milton
    Stefan Zajic
    Patricia L. Judson
    Cindy L. O’Bryant
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 825 - 836
  • [8] EFFECT OF MODERATE HEPATIC IMPAIRMENT ON THE SAFETY AND PHARMACOKINETICS OF REZAFUNGIN
    Ong, Voon
    Sandison, Taylor
    Melara, Rebeca
    Marbury, Thomas
    Huguet, Jade
    Jandourek, Alena
    Flanagan, Shawn
    CRITICAL CARE MEDICINE, 2021, 49 (01) : 334 - 334
  • [9] ASSESSMENT OF REGIONAL IMPACT ON THE PHARMACOKINETICS OF VIR-2218 (BRII-835) IN SUBJECTS WITH CHRONIC HEPATITIS B VIRUS INFECTION
    Zhu, Yali
    Gupta, Sneha
    Li, Chunming
    Zhu, Chong
    Chen, Xiaofei
    Liu, Weihong
    Ma, Ji
    HEPATOLOGY, 2023, 78 : S556 - S557
  • [10] PHARMACOKINETICS OF REMDESIVIR AND ITS METABOLITES IN PARTICIPANTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT
    Regan, S.
    Chang, T.
    Abdelghany, M.
    Llewellyn, J.
    Baysa, A.
    Davies, S.
    Xiao, D.
    Shen, G.
    Girish, S.
    Winter, H.
    Humeniuk, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S17 - S17
12345